Cocrystal Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2834 https://www.cocrystalpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma Inc

Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs - Mar 29th, 2023 12:00 pm
COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. - Mar 22nd, 2023 5:03 pm
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 - Mar 22nd, 2023 12:00 pm
Cocrystal Pharma Announces Participation in Virtual Investor Events - Jan 26th, 2023 1:00 pm
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast - Jan 23rd, 2023 2:00 pm
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A - Dec 19th, 2022 1:00 pm
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 - Dec 1st, 2022 9:05 pm
Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A - Nov 17th, 2022 6:38 pm
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A - Nov 17th, 2022 1:00 pm
COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. - Nov 15th, 2022 4:19 pm
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs - Nov 14th, 2022 1:00 pm
Cocrystal Pharma to Participate in Two Investor Conferences in November - Nov 2nd, 2022 12:00 pm
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza - Nov 1st, 2022 8:05 pm
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 - Oct 26th, 2022 12:00 pm
Cocrystal Pharma to Present at the LD Micro Main Event XV - Oct 19th, 2022 12:00 pm
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 - Oct 13th, 2022 12:00 pm
Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate - Oct 11th, 2022 3:51 pm
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 - Oct 11th, 2022 12:00 pm
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference - Oct 5th, 2022 12:00 pm
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split - Oct 3rd, 2022 8:05 pm